Binge Eating Liraglutide Intervention

NCT03279731 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

36

Enrollment

OTHER

Sponsor class

Stopped The study was not meeting recruitment goals.

Conditions

Binge-Eating Disorder

Interventions

DRUG: Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml
DRUG: Placebo

Sponsor

Kelly Allison

Collaborators

[object Object]